Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.59 |
| ▸ | CACNB1 | Q02641 | 9/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 8/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.59 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463763 | 1.00 | CACNA2D1 (0.59) | CACNA2D1CACNB1CACNA1BCACNA1CSLC6A9 | |
| SCHEMBL5548292 | 0.93 | CACNA2D1 (0.62) | CACNA2D1CACNB1CACNA1BCACNA1CALDH1A1 | |
| SCHEMBL5633544 | 0.81 | CACNA2D1 (0.56) | CACNA2D1CACNB1CACNA1BCACNA1CSLC6A9 | |
| SCHEMBL5634347 | 0.80 | CACNA2D1 (0.54) | CACNA2D1CACNB1CACNA1BCACNA1CSLC6A9 | |
| SCHEMBL5634490 | 0.78 | CACNA2D1 (0.52) | CACNA2D1CACNB1CACNA1BCACNA1CSLC6A9 | |
| SCHEMBL4464060 | 0.78 | CXCR4 (0.52) | MEN1KMT2A | |
| SCHEMBL4464053 | 0.78 | CXCR4 (0.52) | MEN1KMT2A | |
| SCHEMBL5548263 | 0.75 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CSLC6A9 | |
| SCHEMBL5633709 | 0.75 | CYP3A4 (0.51) | CACNA2D1CACNB1CACNA1BCACNA1CSLC6A9 | |
| SCHEMBL4463765 | 0.74 | CACNA2D1 (0.56) | CACNA2D1CACNB1CACNA1BCACNA1CSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | claimed |
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | claimed |
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | disclosed |
| EP-1718633-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165065-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | CACNA2D1 40/4885CACNB1 11/4885CACNA1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.